Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126464
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used treatment, and sensitizing agents, which synergize with radiation, can improve the efficacy of the therapy. In this study we used 435-Br1 cells containing the fluorescent protein (eGFP) gene and the photinus luciferase (PLuc) gene to develop a new brain metastatic cell model in mice through five in vivo/in vitro rounds. BR-eGFP-CMV/Luc-V5 brain metastatic cells induce parenchymal brain metastasis within 60.8 +/- 13.8 days of intracarotid injection in all mice. We used this model to standardize a preclinical chemoradiotherapy protocol comprising three 5.5 Gy fractions delivered on consecutive days (overall dose of 16.5 Gy) which improved survival with regard to controls (60.29 +/- 8.65 vs. 47.20 +/- 11.14). Moreover, the combination of radiotherapy with temozolomide, 60 mg/Kg/day orally for five consecutive days doubled survival time of the mice 121.56 +/- 52.53 days (Kaplan-Meier Curve, p < 0.001). This new preclinical chemoradiotherapy protocol proved useful for the study of radiation response/resistance in brain metastasis, either alone or in combination with new sensitizing agents.
Matèries
Matèries (anglès)
Citació
Citació
MARTÍNEZ ARANDA, Antonio, HERNÁNDEZ, Vanessa, PICÓN, Cristina, MODOLELL, Ignasi, SIERRA JIMÉNEZ, Àngels. Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy. _International Journal of Molecular Sciences_. 2013. Vol. 14, núm. 4, pàgs. 8306-8327. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/126464]